Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 12 Jun 2018
At a glance
- Drugs SPARC-1613 (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Pharmacokinetics
- Sponsors Sun Pharma Advanced Research Company
- 06 Jun 2018 Planned End Date changed from 30 Jun 2018 to 28 Feb 2019.
- 06 Jun 2018 Planned primary completion date changed from 30 Jun 2018 to 28 Feb 2019.
- 02 Feb 2018 Status changed from not yet recruiting to recruiting.